Preclinical Behavioral Science and Social Sciences Review 2023: For USMLE Step 1 and COMLEX-USA Level 1 (2023)
- United States Medical Licensing Examination
- 209 pages
- Shared May 2025
Preclinical Behavioral Science and Social Sciences Review 2023: For USMLE Step 1 and COMLEX-USA Level 1 (2023) provides a clear roadmap to mastering key concepts, boosting your confidence and exam performance.
Preview 16 of 209 pages
See the first 16 pages exactly as they appear in the document.
Page 1 Read page 1 as text
PRECLINICAL BEHAVIORAL SCIENCE AND SOCIAL SCIENCES REVIEW 2023 FOR USMLE STEP 1 AND COMLEX USA LEVEL 1 ® ® USMLE® and United States Medical Licensing Examination® (FSMB), which are not affiliated with Kaplan and were not involved in the production of, and do not endorse, this product. COMLEX USA® is a joint program of the National Board of Medical Examiners (NBME) and the Federation of State Medical Boards is a registered trademark of the National Board of Osteopathic Medical Examiners, Inc. (NBOME), which is not affiliated with Kaplan and was not involved in the production of, and does not endorse, this product
Page 2 Page 3 Read page 3 as text
PRECLINICAL BEHAVIORAL SCIENCE AND SOCIAL SCIENCES REVIEW 2023 FOR USMLE® COMLEX USA® USMLE® STEP 1 AND LEVEL 1 and United States Medical Licensing Examination® is a joint program of the National Board of Medical Examiners (NBME) and the Federation of State Medical Boards (FSMB), which are not affiliated with Kaplan and were not involved in the production of, and do not endorse, this product. COMLEX USA® was not involved in the production of, and does not endorse, this product. is a registered trademark of the National Board of Osteopathic Medical Examiners, Inc. (NBOME), which is not affiliated with Kaplan an
Page 4 Read page 4 as text
USMLE® and United States Medical Licensing Examination® is a joint program of the National Board of Medical Examiners (NBME) and the Federation of State Medical Boards (FSMB), which are not affiliated with Kaplan and were not involved in the production of, and do not endorse, this product. COMLEX USA® is a registered trademark of the National Board of Osteopathic Medical Examiners, Inc. (NBOME), which is not affiliated with Kaplan and was not involved in the production of, and does not endorse, this product. This publication is designed to provide accurate information in regard to the subject matter covered as of its publication date, with the understanding that knowledge and best practice constantly evolve. The publisher is not engaged in rendering medical, legal, accounting, or other professional service. If medical or legal advice or other expert assistance is required, the services of a competent professional should be sought. This publication is not intended for use in clinical practice or the delivery of medical care. To the fullest extent of the law, neither the Publisher nor the Editors assume any liability for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this book. © 2023 by Kaplan North America, LLC Published by Kaplan Medical, a division of Kaplan North America, LLC. 1515 West Cypress Creek Road Fort Lauderdale, Florida 33309 All rights reserved. The text of this publication, or any part thereof, may not be reproduced in any manner whatsoever without written permission from the publisher. This book may not be duplicated or resold, pursuant to the terms of your Kaplan Enrollment Agreement. 10 9 8 7 6 5 4 3 2 1 Course ISBN: 978 1 5062 8441 5 Course Kit ISBN: 978 1 5062 8465 1 Retail ISBN: 978 1 5062 8439 2 Retail Kit ISBN: 978 1 5062 8463 7 Kit items come as a set and should not be broken out and sold separately Kaplan Publishing print books are available at special quantity discounts to use for sales promotions, employee premiums, or educational purposes. For more information or to purchase books, please call the Simon & Schuster special sales department at 866 506 1949
Page 5 Read page 5 as text
Editor Alina Gonzalez Mayo, MD Psychiatrist Department of Veterans Administration Bay Pines, FL Contributor Alice Akunyili, MD Assistant Dean of Academic Affairs Noorda College of Osteopathic Medicine Provo UT The editors would like to acknowledge Kevin Schuller, MD and Kevin Yang, MD for their contributions
Page 6 Read page 6 as text
We want to hear what you think. What do you like or not like about the Notes? Please email us at medfeedback@kaplan.com
Page 7 Read page 7 as text
Table of Contents PART I: EPIDEMIOLOGY AND BIOSTATISTICS CHAPTER 1: Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 CHAPTER 2: Biostatistics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 PART II: BEHAVIORAL SCIENCE CHAPTER 3: Developmental Life Cycle . . . . . . . . . . . . . . . . . . . . . . . 53 CHAPTER 4: Theories of Learning and Behavioral Modification . . . . . . . . . . . 65 CHAPTER 5: Defense Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . 71 CHAPTER 6: Psychological Health and Testing . . . . . . . . . . . . . . . . . . . 77 CHAPTER 7: Substance Use Disorders . . . . . . . . . . . . . . . . . . . . . . . 83 CHAPTER 8: Sleep and Sleep Disorders . . . . . . . . . . . . . . . . . . . . . . 93 CHAPTER 9: Psychiatric (DSM 5) Disorders . . . . . . . . . . . . . . . . . . . . 99 CHAPTER 10: Psychopharmacology . . . . . . . . . . . . . . . . . . . . . . . 117 CHAPTER 11: Brain Function and Neurocognitive Disorders . . . . . . . . . . . 125 CHAPTER 12: Ethics, Law, and Physician Behavior . . . . . . . . . . . . . . . . 135 CHAPTER 13: Health Care Delivery Systems . . . . . . . . . . . . . . . . . . . 157 PART III: SOCIAL SCIENCES CHAPTER 14: Basic Science of Patient Safety . . . . . . . . . . . . . . . . . . 161 INDEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
Page 8 Page 9 Read page 9 as text
PART I EPIDEMIOLOGY AND BIOSTATISTIC
Page 10 Page 11 Read page 11 as text
Epidemiology LEARNING OBJECTIVES ❏ Answer questions about epidemiologic measures ❏ Use knowledge of screening tests ❏ Explain information related to study designs EPIDEMIOLOGIC MEASURES Epidemiology is the study of the distribution and determinants of health related states within a population. It refers to the patterns of disease and the factors that influence those patterns. • Endemic: the usual, expected rate of disease over time; the disease is maintained without much variation within a region • Epidemic: occurrence of disease in excess of the expected rate; usually presents in a larger geographic span than endemics (epidemiology is the study of epidemics) • Pandemic: worldwide epidemic • Epidemic curve: visual description (commonly histogram) of an epidemic curve is disease cases plotted against time; classic signature of an epidemic is a “spike” in time The tools of epidemiology are numbers; the numbers in epidemiology are ratios converted into rates. The denominator is key: who is “at risk” for a particular event or disease state. To determine the rate, compare the number of actual cases with the number of potential cases: ____________ Actual cases Potential cases = Numerator ____________ Denominator = RATE Rates are generally, though not always, per 100,000 persons by the Centers for Disease Control (CDC), but can be per any multiplier. (Vital statistics are usually per 1,000 persons.) A disease may occur in a country at a regular annual rate, which makes it endemic. If there is a sudden rise in the number of cases in a specific month, we say that there is an epidemic. As the disease continues to rise and spread to other countries, it becomes a pandemic. Thus the terminology is related to both the number of cases and its geographical distribution. 1 https://radiologyebook.vn/
Page 12 Read page 12 as text
PART I | EPIDEMIOLOGY AND BIOSTATISTICS Behavioral Science/Social Sciences The graph below represents the incidence of 2 diseases (cases in 100,000). Disease 1 is endemic as the rate of disease is consistent month to month with minor variation in the number of cases. Disease 2 experiences an epidemic in March and April in which the number of cases is in excess of what is expected. January 3 5 February 4 5 March 3 8 April 4 8 May 4 5 June 4 5 July 3 5 August 3 5 Although the data is in 100,000 cases, the variation in disease 1 is still consistent when compared to disease 2. Figure I 1 1. Epidemic vs. Endemic Cases Consider the following scenario. A rural farmer begins to sell meat that is infected with salmonella. Within 2 days, hundreds of nearby villagers begin to experi ence crampy abdominal pain. This is an example of an epidemic. The sudden rise of salmonella gastroenteritis in this village is much higher than the average incidence for the given time period. Now what if the farmer ships 1,000 pounds of infected beef to other regions in the country before he realizes what happened? What can one anticipate would happen? The answer is there would be no change to the endemic rate of gastroen teritis. The farmer is only shipping out 1,000 pounds of beef to a few cities nation wide. Unlike the earlier scenario which addressed the population of a village, this would be the entire nation. Assuming that every person who consumes the beef gets gastroenteritis, that number would not significantly increase the national average of cases and would therefore not significantly change the incidence of the disease nationwide. Incidence and Prevalence Incidence rate (IR) is the rate at which new events occur in a population. • The numerator is the number of new events that occur in a defined period. • The denominator is the population at risk of experiencing this new event during the same period. https://radiologyebook.vn/
Page 13 Read page 13 as text
ChAPTER 1 | EPIDEMIOLOGY Incidence rate = ___________________________________ Number of new events in a specified period Number of persons “exposed to risk” of becoming new cases during this period The IR includes only new cases of the disease that occurred during the specified period, not cases that were diagnosed earlier. This is especially important when working with infectious diseases such as TB and malaria. If, over the course of a year, 5 men are diagnosed with prostate cancer, out of a total male study population of 200 (with no prostate cancer at the beginning of the study period), the IR of prostate cancer in this population would be 0.025 (or 2,500 per 100,000 men years of study). Attack rate is the cumulative incidence of infection in a group of people observed over a period of time during an epidemic, usually in relation to food borne illness. It is measured from the beginning of an outbreak to the end of the outbreak. Attack rate = __________________________________________ Number of exposed people infected with the disease Total number of exposed people Attack rate is also called attack ratio; consider an outbreak of Norwalk virus in which 18 people in separate households become ill. If the population of the community is 1,000, the overall attack rate is _____ 1,000 ́ 100% = 1.8%. 18 ́ 10n Figure I 1 2. Reported Cases of Hepatitis C in the United States Figure I 1 3. Cumulative Incidence 2005–2015 https://radiologyebook.vn/
Page 14 Read page 14 as text
PART I | EPIDEMIOLOGY AND BIOSTATISTICS Behavioral Science/Social Sciences Prevalence is all persons who experience an event in a population. The numerator is all individuals who have an attribute or disease at a particular point in time (or period of time). The denominator is the population at risk of having the attribute or disease at that point in time or midway through the period. Prevalence = ___________________________________ All cases of a disease at a given point/period Total population “at risk” for being cases at a given point/period ́ 10n Prevalence, in other words, is the proportion of people in a population who have a particular disease at a specified point in time (or over a specified period of time). The numerator includes both new cases and old cases (people who remained ill during the specified point or period in time). A case is counted in prevalence until death or recovery occurs. This makes prevalence different from incidence, which includes only new cases in the numerator. Prevalence is most useful for measuring the burden of chronic disease in a population, such as TB, malaria and HIV. For example, the CDC estimated the prevalence of obesity among American adults in 2001 at approximately 20%. Since the number (20%) includes all cases of obesity in the United States, we are talking about prevalence. NOTE Prevalence is a measurement of all individuals (new and old) affected by the disease at a particular time, whereas incidence is a measurement of the number of new individuals who contract a disease during a particular period of time. Point prevalence is useful for comparing disease at different points in time in order to determine whether an outbreak is occurring. We know that the amount of disease present in a population changes over time, but we may need to know how much of a particular disease is present in a population at a single point in time (“snapshot view”). Perhaps we want to know the prevalence of TB in Community A today. To do that, we need to calculate the point prevalence on a given date. The numerator would include all known TB patients who live in Community A that day. The denomina tor would be the population of Community A that day. Period prevalence, on the other hand, is prevalence during a specified period or span of time. The focus is on chronic conditions. In the “prevalence pot,” incident (or new) cases are monitored over time. New cases join pre existing cases to make up total prevalence. Incident Cases General Population at Risk Recovery Prevalent Cases Recovery with Immunity Figure I 1 4. Prevalence Pot Prevalent cases leave the prevalence pot in one of 2 ways: recovery or death. 6 Mortalit https://radiologyebook.vn/
Page 15 Read page 15 as text
ChAPTER 1 | EPIDEMIOLOGY Table I 1 1. Incidence and Prevalence What happens if: New effective treatment is initiated Number of persons dying from the condition increases Incidence no change New effective vaccine gains widespread use decrease no change Additional Federal research dollars are targeted to a specific condition Behavioral risk factors are reduced in the population at large Contacts between infected persons and noninfected persons are reduced For airborne infectious disease? For noninfectious disease? Recovery from the disease is more rapid than it was one year ago Long term survival rates for the disease are increasing no change decrease Prevalence decrease decrease decrease no change decrease NOTE Morbidity rate is the rate of disease in a population at risk (for both incident and prevalent cases), while mortality rate is the rate of death in a population at risk (incident cases only). decrease no change no change no change decrease no change decrease increase Lung Cancer Cases in a Cohort of Heavy Smokers Disease course, if any, for 10 patients 1 2 3 4 5 6 7 8 9 10 1/1/2006 Key: Onset 1/1/2007 Duration Terminal Event Figure 1 2. Calculating Incidence and Prevalence Figure I 1 5. Calculating Incidence and Prevalence https://radiologyebook.vn/
Page 16 Read page 16 as text
PART I | EPIDEMIOLOGY AND BIOSTATISTICS Behavioral Science/Social Sciences Based on the graph above, calculate the following: • Prevalence of lung cancer from 1/1/2006–1/1/2007 o Number of patients who “had” lung cancer in this time period from the graph: (7) o Number of patients at risk in this time period: (9) [exclude patient #2 who died before the time period] o Prevalence: (7/9) o Type of prevalence: (period prevalence) • Incidence of lung cancer from 1/1/2006–1/1/2007 o Number of patients who developed lung cancer in this time period: (4) o Number of patients at risk in this time period: (6) [exclude patients who were already sick at the start of the time period and those who died before the time period] o Incidence: (4/6) Recall Question Prevalence can be defined as which of the following? A. Number of new events in a specified period over the number of persons at risk of becoming new cases during the same period B. Number of exposed people infected with a disease over the total number of exposed people C. All cases of a disease at a given point over the total population at risk for being cases at the same point D. Number of actual cases over potential cases E. Rate of death in a population at risk Answer: C NOTE Use caution using the crude rate. Imagine that in a given city, there are a lot of older, retired people—the crude rate of myocardial infarction will appear higher, even though the rate for each age group has not actually changed. Crude, Specific, and Standardized Rates Crude rate is the actual measured rate for a whole population, e.g., rate of myocardial infarction for a whole population. Specific rate is the actual measured rate for a subgroup of population, e.g., “age specific” or “sex specific” rate. For instance, the rate of myocardial infarction among people age >65 in the population or the rate of breast cancer among the female population. If you are provided specific rates, you can calculate the crude rate. The crude rate of an entire population is a weighted sum of each of the specific rates. The weight ed specific rates that are added together is calculated in the table below. https://radiologyebook.vn/
193 more pages in the full document
Unlock it once and it stays in your library, ready to chat with or turn into flashcards.
Unlock the full documentMore United States Medical Licensing Examination study materials
See all
Certification GuidesFirst Aid for the USMLE Step 1 (2021)
United States Medical Licensing Examination
865 pages122downloadsFeb 2025
Certification GuidesFirst Aid for the USMLE Step 1 2020, 30th Edition (2020)
United States Medical Licensing Examination
876 pages87downloadsFeb 2025
Certification GuidesUSMLE Step 2 CK Lecture Notes 2021: Internal Medicine, 1st Edition (2020)
United States Medical Licensing Examination
1568 pagesMay 2025
Certification GuidesKaplan Medical USMLE Step 1 Lecture Notes (2021)
United States Medical Licensing Examination
2635 pagesMay 2025
Certification GuidesUSMLE Step 2 CK Lecture Notes 2019: Pediatrics (2019)
United States Medical Licensing Examination
591 pagesMay 2025
Certification GuidesFirst Aid for the USMLE Step 1 2024: A Student-to-Student Guide (2024)
United States Medical Licensing Examination
866 pagesMay 2025
Certification GuidesPreclinical Pathology Review 2023: For USMLE Step 1 and COMLEX-USA Level 1 (2023)
United States Medical Licensing Examination
297 pagesMay 2025
Certification GuidesMaster The Boards Usmle, Step 3 (2020)
United States Medical Licensing Examination
1109 pagesMay 2025
Study this document with CramX
Once it is in your library, every tool can work from it.

